Post-transfusion biotin-labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance.
Marianne E McPherson YeePatricia E ZerraJames W McCoyMischa Li CovingtonSean R StowellClinton H JoinerChristopher M LoughBhaveshkumar B DelvadiaCassandra D JosephsonJohn D RobackRoss M FasanoPublished in: Transfusion (2024)
Biotinylation of allogenic RBC can be used to assess the possible effects of RBC antibodies on transfusion survival in individual cases, particularly when it is uncertain if the detected antibodies may result in hemolysis. In the cases presented here, neither WAA nor B-RBC antibodies were associated with significant shortening of B-RBC survival in individuals with SCD.